Elevation Oncology

About Elevation Oncology

Elevation Oncology is a pioneering company in the field of oncology, specializing in the discovery and development of selective cancer therapies. The company focuses on treating patients with solid tumors that have significant unmet medical needs. Leveraging expertise in antibody-drug conjugates (ADCs), Elevation Oncology is advancing a novel pipeline targeting clinically validated markers such as Claudin 18.2 and HER3.

The business model revolves around precision therapies that make genomic testing actionable, aiming to provide tailored treatment options for individual patients. Elevation Oncology primarily serves the healthcare sector, including hospitals, clinics, and specialized cancer treatment centers. The company generates revenue through the development and potential commercialization of its proprietary cancer therapies.

Elevation Oncology operates in the highly specialized oncology market, where the demand for innovative and effective cancer treatments is continually growing. The company's commitment to scientific excellence and its focus on unmet medical needs position it as a key player in the oncology space.